Candel Therapeutics (CADL) Stock: Buy, Sell, or Hold?
CADL - Candel Therapeutics, Inc. Common Stock
$8.38
0.01 (0.12%)
▲
5d:
-5.95%
30d:
-25.78%
90d:
-12.34%
HOLD
LOW Confidence
Analysis Updated: Oct 22, 2026 12:00 AM ET
Earnings: Nov 12, 2026
19d
Get Alerted When CADL Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: CADL shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
📊 HOLD: CADL shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
In-depth Analysis How we analyze
Valuation Analysis: CADL is currently trading at $8.38, which is considered oversold relative to its 30-day fair value range of $9.15 to $11.21. From a valuation perspective, the stock is trading at a discount (Forward PE: -13.4) compared to its historical average (40.5). At these levels, the market is pricing in 0% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, CADL is in a uptrend. Immediate support is located at $7.96, while resistance sits at $10.18.
Market Sentiment: CADL scores 68/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $21.75 (+159.5%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, CADL is in a uptrend. Immediate support is located at $7.96, while resistance sits at $10.18.
Market Sentiment: CADL scores 68/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $21.75 (+159.5%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$9.15 -
$11.21
Company Quality Score
59/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
95.2%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Strong technical setup (68/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 159.5% below Wall St target ($21.75)
- BULLISH: Market expects only 0% annual growth - appears undervalued
- CAUTION: Bottoming setup, but lagging the sector by 15% over 20 days — wait for relative strength
- CAUTION: 5-day price weakness (-5.9%) - monitor closely
Trading Range Analysis
30-Day Trading Range
$9.15 -
$11.21
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$7.96
Resistance Level
$10.18
Current Trend
Uptrend
Technical data as of
Oct 22, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-13.41
Wall Street Target
$21.75
(+159.5%)
PE vs Historical
-13.4 vs 40.5
CHEAP
Share & Embed Analysis
Last updated: October 22, 2026 11:23 PM ET
Data refreshes hourly during market hours. Next update: 12:23 AM
Data refreshes hourly during market hours. Next update: 12:23 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CADL showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
KYMR
Kymera Therapeutics Inc |
STRONG BUY
24 analysts |
$139 | 58 HOLD |
|
ARGX
argenx NV ADR |
STRONG BUY
25 analysts |
$1153 | 52 HOLD |
|
IRD
Opus Genetics, Inc. |
STRONG BUY
18 analysts |
$13 | 63 BUY |
|
DNTH
Dianthus Therapeutics In… |
STRONG BUY
17 analysts |
$141 | 56 HOLD |
|
CLYM
Climb Bio Inc |
STRONG BUY
15 analysts |
$28 | 63 BUY |
